U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Clinical Review Report: Crisaborole Ointment, 2% (Eucrisa): (Pfizer Canada Inc.): Indication: For topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Apr.

Cover of Clinical Review Report: Crisaborole Ointment, 2% (Eucrisa)

Clinical Review Report: Crisaborole Ointment, 2% (Eucrisa): (Pfizer Canada Inc.): Indication: For topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older [Internet].

Show details

References

1.
Canadian Dermatology Association. Eczema. 2018;https://dermatology​.ca​/public-patients/skin/eczema/. Accessed August 28, 2018.
2.
Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–351. [PMC free article: PMC4410183] [PubMed: 24290431]
3.
Lynde C, Barber K, Claveau J, et al. Canadian practical guide for the treatment and management of atopic dermatitis. J Cutan Med Surg. 2005;8: Suppl 5:1–9. [PubMed: 19830906]
4.
Watson W, Kapur S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2011;7: Suppl 1:S4. [PMC free article: PMC3245437] [PubMed: 22166055]
5.
Clinical Study Report: AD-301. A multicenter, randomized, double-blind vehicle -controlled study of the safety and effecacy of AN2728 topical ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis [CONFIDENTIAL internal manufacturer’s report]. Palo Alto (CA): Anacor Pharmaceuticals, Inc.; 2015 Nov 23.
6.
Clinical Study Report: AD-302. A multicenter, randomized, double-blind vehicle -controlled study of the safety and effecacy of AN2728 topical ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis [CONFIDENTIAL internal manufacturer’s report]. Palo Alto (CA): Anacor Pharmaceuticals, Inc.; 2015 Nov 23.
7.
Bobotsis R, Fleming P, Eshtiaghi P, Cresswell-Melville A, Drucker AM. A Canadian adult cross-sectional survey of the burden of moderate to severe atopic dermatitis. J Cutan Med Surg. 2018;22(4):445–446. [PubMed: 29927311]
8.
Bridgman AC, Eshtiaghi P, Cresswell-Melville A, Ramien M, Drucker AM. The burden of moderate to severe atopic dermatitis in Canadian children: a cross-sectional survey. J Cutan Med Surg. 2018;22(4):443–444. [PubMed: 29927316]
9.
Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. [PMC free article: PMC4326095] [PubMed: 24813302]
10.
Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37):1–191. [PMC free article: PMC4782813] [PubMed: 11134919]
11.
Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349. [PMC free article: PMC4410179] [PubMed: 24813298]
12.
American Academy of Dermatology. Atopic dermatitis: Recommendations for the use of systemic immunomodulatory agents. https://www​.aad.org/practicecenter​/quality​/clinical-guidelines​/atopic-dermatitis​/phototherapy-and-systemic-agents​/recommendations-for-systemic-immunomodulatory-agents. Accessed August 28, 2018.
13.
Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol. 2006;118(1):152–169. [PubMed: 16815151]
14.
e-CPS. Atopic dermatitis. Ottawa (ON): Canadian Pharmaceutical Association; 2018:https://www​.e-therapeutics.ca. Accessed August 28, 2018.
15.
Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.[Erratum appears in J Am Acad Dermatol. 2017 Apr;76(4):777; PMID: 28169014]. J Am Acad Dermatol. 2016;75(3):494–503.e496. [PubMed: 27417017]
16.
Paller AS. Clarification of methodology and further results from the pivotal phase 3 study of crisaborole for mild-moderate atopic dermatitis. Br J Dermatol. 2018;178(3):663–664. [PubMed: 29194568]
17.
Center for Drug Evaluation and Research. Medical review: Eucrisa (Crisaborole). Anacor Pharmaceuticals, Inc. Application no.: 207695. Approval date: 14/12/2016. Rockville (MD): U.S. Food and Drug Administration (FDA); 2016: https://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2016/207695Orig1s000TOC.cfm. Accessed August 28, 2018.
18.
Center for Drug Evaluation and Research. Statistical review: Eucrisa (Crisaborole). Anacor Pharmaceuticals, Inc. Application no.: 207695. Approval date: 14/12/2016. Rockville (MD): U.S. Food and Drug Administration (FDA); 2016: https://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2016/207695Orig1s000TOC.cfm. Accessed August 28, 2018.
19.
CDR submission: Eucrisa (Crisaborole) 2% ointment for topical use. Company: Pfizer Canada, Inc [CONFIDENTIAL manufacturer’s submission]. Pointe-Claire/Dorval (QU): Pfizer Canada, Inc; 2018 May 25.
20.
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis Acta Derm Venereol Suppl (Stockh). 1980;92:44–47.
21.
Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2016;74(2):288–294. [PubMed: 26685719]
22.
Finlay AY, Khan GK. Dermatology Quality of Life Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. [PubMed: 8033378]
23.
Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997–1035. [PubMed: 18795920]
24.
Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942–949. [PubMed: 7662573]
25.
Dodington SR, Basra MK, Finlay AY, Salek MS. The Dermatitis Family Impact questionnaire: a review of its measurement properties and clinical application. Br J Dermatol. 2013;169(1):31–46. [PubMed: 23834116]
26.
Pfizer Canada Inc response to July 27, 2018 CDR request for additional information regarding the Crisaborole CDR review: Subgroup ananlyses based on baseline disease severity [CONFIDENTIAL additional manufacturer’s information]. Pointe Claire (QC): Pfizer Canada Inc.; 2018
27.
American Academy of Dermatology. Atopic dermatitis clinical guideline, 2014. 2014; https://www​.aad.org/practicecenter​/quality​/clinical-guidelines/atopic-dermatitis. Accessed August 28, 2018.
28.
Ahluwalia J, Udkoff J, Waldman A, Borok J, Eichenfield LF. Phosphodiesterase 4 inhibitor therapies for atopic dermatitis: progress and outlook. Drugs. 2017;77(13):1389–1397. [PubMed: 28681318]
29.
Clinical Study Report: AD-303. A multicenter, open-label study of the long-term safety of AN2728 topical ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis [CONFIDENTIAL internal manufacturer’s report]. Palo Alto (CA): Anacor Pharmaceuticals, Inc.; 2015 Nov 24.
30.
Food and Drug Administration. Draft guidance on Pimecrolimus. Silver Spring (MD): FDA; 2012 May.
31.
Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27–33. [PubMed: 25613671]
32.
Yosipovitch G, Simpson EL, Bushmakin AG, et al. Assessment of pruritus in atopic dermatitis. Itch. 2018;3(2):e13.
33.
Heinl D, Prinsen CAC, Sach T, et al. Measurement properties of quality-of-life measurement instruments for infants, children and adolescents with eczema: a systematic review. Br J Dermatol. 2017;176(4):878–889. [PubMed: 27543747]
34.
Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG. The family impact of childhood atopic dermatitis: the Dermatitis Impact questionnaire. Br J Dermatol. 1998;138:107–113. [PubMed: 9536231]
35.
Lewis-Jones MS, Finlay AY, Dykes PJ. The Infants’ Dermatitis Quality of Life Index. Br J Dermatol. 2001;144:104–110. [PubMed: 11167690]
36.
Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641–649.e645. [PubMed: 28823881]
37.
Crisaborole 2% ointment for the treatment of mild-to-moderate atopic dermatitis systematic literuature review and network meta-analysis: final report. CDR submission: Eucrisa (Crisaborole) 2% ointment for topical use. Company: Pfizer Canada, Inc [CONFIDENTIAL manufacturer’s submission]. Dorval, Pointe Claire (QU): Pfizer Canada, Inc.; 2018 May 25.
38.
Institute for Clinical and Economic Review. Dupilumab and crisaborole for atopic dermatitis: effectiveness and value: evidence report. Boston (MA): ICER; 2017: https://icer-review​.org​/wp-content/uploads​/2016/10/MWCEPAC_ATOPIC​_EVIDENCE_REPORT_051217.pdf. Accessed August 28, 2018.
Copyright © 2019 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK542343
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (2.1M)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On
  • References - Clinical Review Report: Crisaborole Ointment, 2% (Eucrisa)
    References - Clinical Review Report: Crisaborole Ointment, 2% (Eucrisa)
  • Parvalbumins
    Parvalbumins
    Low molecular weight, calcium binding muscle proteins. Their physiological function is possibly related to the contractile process.<br/>Year introduced: 1991(1977)
    MeSH
  • Patient Acuity
    Patient Acuity
    An assessment of a patient's illness, its chronicity, severity, and other qualitative aspects.<br/>Year introduced: 2013
    MeSH

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...